Can Tricky Elderly AML Population Justify Weak Data? Fate Of Genzyme's Clolar and Vion's Onrigin Rests With ODAC

FDA's briefing documents for the Sept. 1 review suggest the single-arm Phase II trials are not sufficient; the wild card will be whether the panel thinks better trials can be done in that population.